Use of radiolabeled antibodies in the treatment of childhood acute leukemia.
Despite advances in therapy for acute leukemia, relapse continues to be the major cause of treatment failure. Hematopoietic stem cell transplant can rescue some patients after relapse, but the ability to escalate the intensity of preparative regimens is limited by toxicity to normal organs. Radiolabeled monoclonal antibodies against hematopoietic antigens have emerged as an alternative to deliver targeted supplemental radiation to sites of leukemic involvement while relatively sparing normal organs. This paper will review the rationale for using this approach, our current experience with radiolabeled anti-CD45 antibody, and the potential challenges encountered in treating children with radiolabeled antibodies.
Nemecek
Eneida R
ER
Divisions of Clinical Research and Pediatric Hematology/Oncology, Fred Hutchinson Cancer Research Center and University of Washington, PO Box 19024, Seattle, WA 98109-1024, USA. enemecek@fhcrc.org
Matthews
Dana C
DC
D000208:Acute Disease; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002648:Child; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D007945:Leukemia, Lymphoid / Q000276:immunology / Q000628:therapy*; D007951:Leukemia, Myeloid / Q000276:immunology / Q000628:therapy*; D017493:Leukocyte Common Antigens / Q000276:immunology*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D018796:Immunoconjugates; D017493:Leukocyte Common Antigens